Belite BioNASDAQ: BLTE

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

29 April 2022

Next earnings report:

14 November 2024

Last dividends:

N/A

Next dividends:

N/A
$2.14 B
0%vs. 3y high
81%vs. sector
-vs. 3y high
-vs. sector
-23%vs. 3y high
97%vs. sector
-vs. 3y high
-vs. sector

Price

regular market | Fri, 01 Nov 2024 13:30:00 GMT
$69.90+$3.29(+4.94%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

BLTE Latest News

Belite Bio Announces Exercise of Warrants for US$28.75 Million Gross Proceeds
globenewswire.com03 November 2024 Sentiment: -

SAN DIEGO, Nov. 03, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announces the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 651,380 ordinary shares of the Company originally issued in April 2024, at an exercise price of US$44.14 per share. The gross proceeds to the Company from the exercise of the warrants are expected to be approximately US$28.75 million. The Company intends to use the net proceeds from the offering for general corporate purposes.

Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer
globenewswire.com01 September 2024 Sentiment: POSITIVE

SAN DIEGO, Sept. 01, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that its board of directors has appointed Hendrik P. N. Scholl, MD, MA, as the Chief Medical Officer of the Company, effective immediately. Dr. Scholl is the foremost globally recognized authority on Stargardt disease and age-related macular degeneration (AMD), bringing decades of expertise in treating retinal diseases, including the two key indications targeted by Belite Bio's lead drug candidate, Tinlarebant.

Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
globenewswire.com09 August 2024 Sentiment: POSITIVE

SAN DIEGO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced its financial results for the second quarter ended June 30, 2024, and provided a general business update.

Belite Bio to Host Webcast on August 12, 2024, to Discuss Second Quarter 2024 Financial Results
globenewswire.com05 August 2024 Sentiment: POSITIVE

SAN DIEGO, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Monday, August 12, 2024, at 4:30 p.m. Eastern Time to discuss the Company's financial results and provide a business update for the second quarter ended June 30, 2024.

Belite Bio, Inc (BLTE) Q1 2024 Earnings Call Transcript
Seeking Alpha14 May 2024 Sentiment: POSITIVE

Belite Bio, Inc. (NASDAQ:BLTE ) Q1 2024 Earnings Conference Call will be held on May 14, 2024 at 4:30 PM ET. Participants include Tom Lin, Nathan Mata, and Hao-Yuan Chuang. Conference Call Participants are Yi Chen and Basma Radwan. Operator welcomes everyone to the discussion on Belite Bio's First Quarter 2024 Financial Results.

Does Belite Bio (BLTE) Have the Potential to Rally 41.14% as Wall Street Analysts Expect?
Zacks Investment Research10 April 2024 Sentiment: POSITIVE

The average price target suggests a potential increase of 41.1% for Belite Bio (BLTE). Although studies show that this metric may not always be reliable, an increase in earnings estimates could indicate a potential upside for the stock in the near future.

Belite Bio, Inc (BLTE) Q4 2023 Earnings Call Transcript
Seeking Alpha12 March 2024 Sentiment: NEUTRAL

Belite Bio, Inc (BLTE) Q4 2023 Earnings Call Transcript

Belite Bio, Inc (BLTE) Q3 2023 Earnings Call Transcript
Seeking Alpha14 November 2023 Sentiment: POSITIVE

Belite Bio, Inc. (NASDAQ:BLTE ) Q3 2023 Earnings Conference Call November 14, 2023 4:30 PM ET Company Participants Tom Lin - Chairman and Chief Executive Officer Nathan Mata - Chief Scientific Officer Hao-Yuan Chuang - Chief Financial Officer Conference Call Participants Jennifer Kim - Kento Basma Radwan - Leerink Partners Yi Chen - HC Wainwright Bruce Jackson - The Benchmark Company Operator Hello and thank you for joining us to discuss Belite's Third Quarter 2023 Financial Results. Joining the call is Dr. Tom Lin, Chairman and CEO, Dr. Nathan Mata, Chief Scientific Officer, and Hao-Wan Zhang, Chief Financial Officer of BeLite Bio.

Belite Bio (BLTE) Stock Surges 72% in a Month: Here's Why
Zacks Investment Research21 August 2023 Sentiment: POSITIVE

Belite Bio (BLTE) rises 72% in a month due to encouraging progress on the development of the company's lead product candidate Tinlarebant, which is being developed to treat several eye diseases.

Belite Bio, Inc (BLTE) Q2 2023 Earnings Call Transcript
Seeking Alpha13 August 2023 Sentiment: POSITIVE

Belite Bio, Inc (NASDAQ:BLTE ) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Tom Lin - Chairman and Chief Executive Officer Nathan Mata - Chief Scientific Officer Hao-Yuan Chuang - Chief Financial Officer Conference Call Participants Basma Radwan - Leerink Partners Jennifer Kim - Cantor Fitzgerald & Co. Yi Chen - HC Wainwright & Co, LLC Bruce Jackson - The Benchmark Company Operator Good morning, and welcome to the Belite Bio Q2 2023 Financial Results Conference Call. At this time, all attendees are in a listen-only mode.

What type of business is Belite Bio?

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

What sector is Belite Bio in?

Belite Bio is in the Healthcare sector

What industry is Belite Bio in?

Belite Bio is in the Biotechnology industry

What country is Belite Bio from?

Belite Bio is headquartered in United States

When did Belite Bio go public?

Belite Bio initial public offering (IPO) was on 29 April 2022

What is Belite Bio website?

https://www.belitebio.com

Is Belite Bio in the S&P 500?

No, Belite Bio is not included in the S&P 500 index

Is Belite Bio in the NASDAQ 100?

No, Belite Bio is not included in the NASDAQ 100 index

Is Belite Bio in the Dow Jones?

No, Belite Bio is not included in the Dow Jones index

When was Belite Bio the previous earnings report?

No data

When does Belite Bio earnings report?

The next expected earnings date for Belite Bio is 14 November 2024